Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5 cm: A propensity score matching study

详细信息    查看全文

• 作者：Minpeng Li¹ ; Jun He¹ ; Meng Pan ; Yuan Yu ; Zhuang Pan ; Bin Xu ; Jiye Zhu ; ^{richardabson198@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Hepatocellular carcinoma ; Iodine-125 ; Propensity score matching ; Transarterial chemoembolization
• 刊名：Digestive and Liver Disease
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：48
• 期：9
• 页码：1082-1087
• 全文大小：907 K

文摘

Both iodine-125 implantation and transarterial chemoembolization (TACE) are feasible options for hepatocellular carcinoma (HCC). The aim of the research is to investigate whether iodine-125 implantation combined with TACE could improve the overall survival of patients with HCC of 3–5 cm.

Methods

144 patients with HCC of 3–5 cm who underwent iodine-125 implantation plus TACE and TACE alone were retrospectively enrolled in this study. To reduce the selection bias, 55 matched pairs of patients were generated by propensity score matching (PSM). Their overall survival was compared by the Kaplan–Meier method. Independent prognostic factors were identified by Cox proportional hazards regression model.

Results

patients receiving iodine-125 implantation plus TACE have significantly better overall survival than patients receiving TACE alone (P < 0.001). After PSM, treatment of iodine-125 plus TACE still provide better survival (1-year, 89.1% vs. 65.5%; 3-year, 51.0% vs. 7.4%; P < 0.001). In multivariate analysis, BCLC stage, vascular invasion and treatment modality independently predicted the prognosis. No severe adverse events occurred in both groups.

Conclusion

for HCC patients of 3–5 cm for whom surgical intervention is not an option, iodine-125 implantation combined with TACE might be an effective and viable alternative to provide better overall survival.